Broadwood Partners, L.p. bought $6.0M of LCTX
director, owner at Lineage Cell Therapeutics, Inc.. 7,894,737 shares at an average of $0.76, traded Jan 27, 2025, filed Jan 28, 2025.
Score components
- +15RoleDirector
- +25Trade size$6.0M at market
- +3Relative to holdingsHoldings up 19%
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -9.5%, 3m -25.4%, 6m +69.8%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000919574-25-000555, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 27, 2025 | POpen-market purchase Common Shares | +7,894,737 | $0.76 | $6.0M | 49,560,992 | Jan 28, 2025 |
| Jan 27, 2025 | POpen-market purchase Common Sharesindirect: See Footnote | +0 | $0.00 | $0 | 49,560,992 | Jan 28, 2025 |
| Jan 27, 2025 | POpen-market purchase Common Warrantderivative | +7,894,737 | $0.00 | $0 | 7,894,737 | Jan 28, 2025 |
| Jan 27, 2025 | POpen-market purchase Common Warrantderivativeindirect: See Footnote | +0 | $0.00 | $0 | 7,894,737 | Jan 28, 2025 |
Related signals
Other insiders at Lineage Cell Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 32Weak | LCTXbuy Lineage Cell Therapeutics, Inc. | Brian M Culley President and CEO | $24k 15,000 shares | +6% | |
| 47Moderate | Lineage Cell Therapeutics, Inc. | Jill Ann Howe Chief Financial Officer | $8,850 15,000 shares | +143% | |
| 40Moderate | Lineage Cell Therapeutics, Inc. | George A. Samuel III General Counsel | $9,000 15,000 shares | +209% | |
| 33Weak | Lineage Cell Therapeutics, Inc. | Michael H. Mulroy director | $23k 40,000 shares | +15% | |
| 46Moderate | Lineage Cell Therapeutics, Inc. | Brian M Culley President and CEO | $24k 40,000 shares | +26% | |
| 48Moderate | LCTXbuy Lineage Cell Therapeutics, Inc. | Jill Ann Howe Chief Financial Officer | $9,345 10,500 shares | - | |
| 36Weak | LCTXbuy Lineage Cell Therapeutics, Inc. | Brian M Culley President and CEO | $11k 10,000 shares | +7% | |
| 47Moderate | Lineage Cell Therapeutics, Inc. | Don M Bailey director | $100k 96,155 shares | +153% | |
| 65Notable | Lineage Cell Therapeutics, Inc. | Broadwood Partners, L.p. director, owner | $7.0M 6,730,770 shares | +19% | |
| 27Weak | LCTXbuy Lineage Cell Therapeutics, Inc. | Anula Jayasuriya director | $11k 10,000 shares | - |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.